Aegis-I: CSL112 in subjects with Acute MI

CONFIDENTIAL - HUMAN CLINICAL TRIAL Aegis-1 abstract This is a Phase 2b, multicenter, international study designed to determine the safest dose of CSL112. Patients will be recruited from the hospital who have had a recent heart attack. Eligible patients will be randomized to receive either a "high dose", a "low dose" of study drug or placebo via an IV infusion. Patients will have a total of 4 infusions of study drug over the course of 4 weeks. Patients will be followed adverse events via physical assessments as well as blood and urine tests. It is proposed that 1200 patients be randomized worldwide with approximately 20 patients enrolled at University of Kentucky.